FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
Liang Wenfeng: All About The Brain Behind DeepSeek
Liang Wenfeng started buying thousands of Nvidia chips as part of an AI side project, then launched DeepSeek in 2023.
News Medical on MSN3d
New Brain Mapping Uncovers Anxiety Drug Target
Weill Cornell Medicine investigators have identified in a preclinical model a specific brain circuit whose inhibition appears to reduce anxiety ...
What the Lewiston shooter’s brain injury can tell us about blast exposure in the military
Experts say the gunman’s brain tissue points to traumatic injury ‘likely’ caused by blasts in the line of duty; the Army disagrees but is taking steps to limit exposure.
Daily Voice Tolland County CT on MSN17h
FDA Approves First Non-Opioid Painkiller In 20+ Years: 'A Historic Milestone'
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
The York Dispatch5d
We are in a mental health crisis. A ‘moonshot’ is needed
Rates of PTSD combined with anxiety disorders or diagnoses of depression increased by 177% and 138% in only five years, from ...
Stockhead on MSN2d
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder
Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...
Hosted on MSN7h
Can FDA-approved Journavx Put An End To Death From Opioids?
This approval is considered a major breakthrough in treating acute pain without the need for opioid medication as reliance on ...
Managed Healthcare Executive16h
FDA Approves Journavx as a New Non-Opioid Pain Med for Acute Pain Relief
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
Peninsula Daily News4d
How EchoXen Targets Tinnitus and Hearing Loss—A Comprehensive Study
Maintaining optimal ear health often falls by the wayside in today’s fast-paced world. Many individuals struggle with ...